An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer

Experimental Cell Research
Huahui YuYunbin Ye

Abstract

MUC1 is a tumor-associated antigen (TAA) overexpressed in many tumor types, which makes it an attractive target for cancer immunotherapy. However, this marker is a non-mutated antigen without high immunogenicity. In this study, we designed several new altered peptides by replacing amino acids in their sequences, which were derived from a low-affinity MUC1 peptide, thus bypassing immune tolerance. Compared to the wild-type (WT) peptide, the altered MUC1 peptides (MUC11081-1089L2, MUC11156-1164L2, MUC11068-1076Y1) showed higher affinity to the HLA-A0201 molecule and stronger immunogenicity. Furthermore, these altered peptides resulted in the generation of more cytotoxic T lymphocytes (CTLs) that could cross-recognize gastric cancer cells expressing WT MUC1 peptides, in an HLA-A0201-restricted manner. In addition, M1.1 (MUC1950-958), a promising antitumor peptide that has been tested in multiple tumors, was not able to induce stronger antitumor responses. Collectively, our results demonstrated that altered peptides from MUC1, as potential HLA-A0201-restricted CTL epitopes, could serve as peptide vaccines or constitute components of peptide-loaded dendritic cell vaccines for gastric cancer treatment.

References

Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R CibottiP Kourilsky
Feb 12, 1998·The Journal of Clinical Investigation·V KaranikasI F McKenzie
Jan 25, 2002·International Journal of Cancer. Journal International Du Cancer·Cristina MusselliPhilip O Livingston
May 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Antonio ScardinoKostas Kosmatopoulos
Nov 20, 2002·Cancer Immunology, Immunotherapy : CII·Gabriele PecherEckhard Thiel
Jan 13, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yih-Huei UenJaw-Yuan Wang
Aug 25, 2007·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yong-Guo CaiShi-Ming Yang
Apr 1, 2009·The Journal of Experimental Medicine·Gabrielle A RizzutoAlan N Houghton
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin A CheeverLynn M Matrisian
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Kimberly R JordanJill E Slansky
Jul 20, 2010·Immunotherapy·Richard E BeatsonJoy M Burchell
Oct 10, 2015·Leukemia·O A HaabethB Bogen
Jan 24, 2017·Cell·Matthew H SpitzerEdgar G Engleman
May 12, 2017·Current Opinion in Biotechnology·Michael T Bethune, Alok V Joglekar
Jul 6, 2017·Nature·Patrick A OttCatherine J Wu
Jul 25, 2017·Current Opinion in Immunology·Takumi KumaiEsteban Celis
Feb 7, 2018·Immunology Letters·Qian SongXiang-Hua Wu
Dec 7, 2018·Science Translational Medicine·Céline M LaumontClaude Perreault
Feb 8, 2019·Proceedings of the National Academy of Sciences of the United States of America·Christopher A ParksLarry R Pease

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

The International Journal of Biological Markers
Silvia von Mensdorff-PouillyP Kenemans
Expert Opinion on Investigational Drugs
D W Miles, J Taylor-Papadimitriou
Medicinal Research Reviews
Maryam Sadat NabaviniaKhalil Abnous
© 2021 Meta ULC. All rights reserved